Oral Pre-exposure Prophylaxis (PrEP) to Prevent HIV: a Systematic Review and Meta-analysis of Clinical Effectiveness, Safety, Adherence and Risk Compensation in All Populations

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 May 11

PMID 35545381

Authors

Eamon O Murchu

Liam Marshall

Conor Teljeur

Patricia Harrington

Catherine Hayes

Patrick Moran

Mairin Ryan

Affiliations

Soon will be listed here.

Abstract

Objective: To conduct a systematic review and meta-analysis of randomised controlled trials (RCTs) of the effectiveness and safety of oral pre-exposure prophylaxis (PrEP) to prevent HIV.

Methods: Databases (PubMed, Embase and the Cochrane Register of Controlled Trials) were searched up to 5 July 2020. Search terms for 'HIV' were combined with terms for 'PrEP' or 'tenofovir/emtricitabine'. RCTs were included that compared oral tenofovir-containing PrEP to placebo, no treatment or alternative medication/dosing schedule. The primary outcome was the rate ratio (RR) of HIV infection using a modified intention-to-treat analysis. Secondary outcomes included safety, adherence and risk compensation. All analyses were stratified a priori by population: men who have sex with men (MSM), serodiscordant couples, heterosexuals and people who inject drugs (PWIDs). The quality of individual studies was assessed using the Cochrane risk-of-bias tool, and the certainty of evidence was assessed using GRADE.

Results: Of 2803 unique records, 15 RCTs met our inclusion criteria. Over 25 000 participants were included, encompassing 38 289 person-years of follow-up data. PrEP was found to be effective in MSM (RR 0.25, 95% CI 0.1 to 0.61; absolute rate difference (RD) -0.03, 95% CI -0.01 to -0.05), serodiscordant couples (RR 0.25, 95% CI 0.14 to 0.46; RD -0.01, 95% CI -0.01 to -0.02) and PWID (RR 0.51, 95% CI 0.29 to 0.92; RD -0.00, 95% CI -0.00 to -0.01), but not in heterosexuals (RR 0.77, 95% CI 0.46 to 1.29). Efficacy was strongly associated with adherence (p<0.01). PrEP was found to be safe, but unrecognised HIV at enrolment increased the risk of viral drug resistance mutations. Evidence for behaviour change or an increase in sexually transmitted infections was not found.

Conclusions: PrEP is safe and effective in MSM, serodiscordant couples and PWIDs. Additional research is needed prior to recommending PrEP in heterosexuals. No RCTs reported effectiveness or safety data for other high-risk groups, such as transgender women and sex workers.

Prospero Registration Number: CRD42017065937.

Citing Articles

Cost-effectiveness of HIV pre-exposure prophylaxis among female sex workers in Iran.

Moameri H, Goudarzi R, Haghdoost A, Gouya M, Saberi P, Mirzazadeh A Sci Rep. 2025; 15(1):7747.

PMID: 40044976 PMC: 11882906. DOI: 10.1038/s41598-025-92099-1.

Knowledge and Awareness of Pre-Exposure Prophylaxis Among Men in Sub-Saharan Africa: A Scoping Review Protocol.

Badru O, Hlongwa M, Adeagbo O Health Sci Rep. 2025; 8(1):e70377.

PMID: 39877871 PMC: 11772214. DOI: 10.1002/hsr2.70377.

Determinants of Familiarity and Experience with HIV Pre-Exposure Prophylaxis in Primary Care Providers in Ontario, Canada.

Martinez-Cajas J, Alvarado B, Rapino C, Nagy E, Guan T, Cofie N J Prim Care Community Health. 2025; 16():21501319251315566.

PMID: 39846350 PMC: 11755537. DOI: 10.1177/21501319251315566.

COVID-19 impact on HIV PrEP uptake and retention at selected health facilities in Eswatini.

Ginindza M, Ncube N, Coetzee R Afr J Prim Health Care Fam Med. 2025; 16(1):e1-e6.

PMID: 39846107 PMC: 11736549. DOI: 10.4102/phcfm.v16i1.4685.

Cross-sectional study measuring the level and relationship of awareness, attitude and willingness to use HIV pre-exposure prophylaxis in Davao City, Philippines.

Gabucan V BMJ Open. 2025; 15(1):e091977.

PMID: 39832991 PMC: 11749391. DOI: 10.1136/bmjopen-2024-091977.

References

Rucker G, Schwarzer G, Carpenter J . Arcsine test for publication bias in meta-analyses with binary outcomes. Stat Med. 2007; 27(5):746-63. DOI: 10.1002/sim.2971. View

Hosek S, Siberry G, Bell M, Lally M, Kapogiannis B, Green K . The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013; 62(4):447-56. PMC: 3656981. DOI: 10.1097/QAI.0b013e3182801081. View

Mayer K, Molina J, Thompson M, Anderson P, Mounzer K, De Wet J . Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020; 396(10246):239-254. PMC: 9665936. DOI: 10.1016/S0140-6736(20)31065-5. View

Freeborn K, Portillo C . Does pre-exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review. J Clin Nurs. 2017; 27(17-18):3254-3265. PMC: 5797507. DOI: 10.1111/jocn.13990. View

Grohskopf L, Chillag K, Gvetadze R, Liu A, Thompson M, Mayer K . Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013; 64(1):79-86. DOI: 10.1097/QAI.0b013e31828ece33. View

McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

Mutua G, Sanders E, Mugo P, Anzala O, Haberer J, Bangsberg D . Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012; 7(4):e33103. PMC: 3325227. DOI: 10.1371/journal.pone.0033103. View

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-90. DOI: 10.1016/S0140-6736(13)61127-7. View

Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M . Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14(9):820-9. PMC: 6107918. DOI: 10.1016/S1473-3099(14)70847-3. View

10.

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

11.

Bekker L, Roux S, Sebastien E, Yola N, Amico K, Hughes J . Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2017; 5(2):e68-e78. PMC: 6107917. DOI: 10.1016/S2352-3018(17)30156-X. View

12.

Beisemann M, Doebler P, Holling H . Comparison of random-effects meta-analysis models for the relative risk in the case of rare events: A simulation study. Biom J. 2020; 62(7):1597-1630. DOI: 10.1002/bimj.201900379. View

13.

Kibengo F, Ruzagira E, Katende D, Bwanika A, Bahemuka U, Haberer J . Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One. 2013; 8(9):e74314. PMC: 3784443. DOI: 10.1371/journal.pone.0074314. View

14.

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

15.

Huang X, Hou J, Song A, Liu X, Yang X, Xu J . Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018; 9:799. PMC: 6131617. DOI: 10.3389/fphar.2018.00799. View

16.

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

17.

Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K . Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007; 2(5):e27. PMC: 1876601. DOI: 10.1371/journal.pctr.0020027. View

18.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

19.

Chen Y, Hong C, Ning Y, Su X . Meta-analysis of studies with bivariate binary outcomes: a marginal beta-binomial model approach. Stat Med. 2015; 35(1):21-40. PMC: 5789784. DOI: 10.1002/sim.6620. View

20.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View